FDA approves encorafenib in combination with cetuximab for treatment of metastatic colorectal cancer with a BRAFV600E mutation

Approval was based on data from phase III BEACON CRC trial which reported improved overall survival with the combination versus control group comprising irinotecan with cetuximab or FOLFIRI with cetuximab (median 8.4 vs. 5.4 months, respectively)

Biospace Inc.